Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Resmed (RSMDF) over the last 4 years, with Q3 2021 value amounting to $8.5 million.

  • Resmed's Amortization of Deferred Charges fell 1827.86% to $8.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $32.9 million, marking a year-over-year increase of 604.54%. This contributed to the annual value of $34.8 million for FY2021, which is 3105.61% up from last year.
  • Per Resmed's latest filing, its Amortization of Deferred Charges stood at $8.5 million for Q3 2021, which was down 1827.86% from $9.0 million recorded in Q2 2021.
  • Resmed's 5-year Amortization of Deferred Charges high stood at $10.4 million for Q3 2020, and its period low was $6.0 million during Q3 2019.
  • For the 3-year period, Resmed's Amortization of Deferred Charges averaged around $7.8 million, with its median value being $7.5 million (2020).
  • As far as peak fluctuations go, Resmed's Amortization of Deferred Charges skyrocketed by 7477.78% in 2020, and later tumbled by 1827.86% in 2021.
  • Quarter analysis of 3 years shows Resmed's Amortization of Deferred Charges stood at $6.4 million in 2019, then rose by 17.75% to $7.5 million in 2020, then grew by 13.73% to $8.5 million in 2021.
  • Its Amortization of Deferred Charges stands at $8.5 million for Q3 2021, versus $9.0 million for Q2 2021 and $7.9 million for Q1 2021.